A Blank Rome team represented iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, in entering into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement ("PIPE") financing that is expected to result in gross proceeds of approximately $26 million to the company before placement agent fees and offering expenses.
iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, through key development milestones, as well as to continue to progress its other preclinical pipeline assets, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes.
For more information about this financing, please read the press release: iBio Announces $26 Million Private Placement (January 9, 2026).
The Blank Rome team was led by Leslie Marlow, Melissa Palat Murawsky, and Jamie L. Plisner, with assistance from Thomas E. Carroll, Alyson Bright, and Christy Grzan.
